NHMRC project grant success for CSRH

5 Dec 2016

CSRH was successful in three applications for Project Grants recently announced by the National Health and Medical Reseach Council. This is a great outcome and we look forward to these projects adding to our vibrant program of work from 2017.

Identifying factors that improve the health of prisoners who inject drugs

Prisoners who inject drugs are highly marginalised with high rates of unresolved health and social issues and high rates of return to prison. Little is known, however, about how this group manages after release from prison. This qualitative project will allow ex-prisoners to tell their own stories of the challenges they have had and what strategies (formal and informal) they have used with the aim of informing responses in prisons and in the community setting.

Chief Investigators: Carla Treloar, Mark Stoove (Burnet Institute), Paul Dietze (Burnet Institute), Eileen Baldry (School of Social Sciences, UNSW), Peter Higgs (La Trobe).

Crystal methamphetamine use, sex and risk practice among gay and bisexual men

The use of the drug “crystal” (also known as “ice”) during sex has become far more common among gay and bisexual men (GBM) in Australia in recent years. Diseases such as HIV and hepatitis C are easily transmitted between GBM who inject crystal during sex. This innovative study will interview GBM who combine crystal use with sex, and health promotion professionals, in order to develop effective ways of reducing harms and preventing the transmission of diseases in sexual contexts.

Chief Investigators: Carla Treloar, Gary Dowsett (ARCSHS, La Trobe), Max Hopwood, Martin Holt, Toby Lea, Peter Aggleton.

Risk of hepatitis C reinfection among people with current injecting drug use following successful HCV treatment

In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.

Chief Investigators: Jason Grebely (Kirby Institute), Andrew Lloyd (Kirby Institute), Carla Treloar, Janaki Amin (Kirby Institute), Louise Degenhardt (NDARC), Rowena Bull (School of Medical Sciences, UNSW), Tanya Applegate (Kirby Institute), Adrian Dunlop (Hunter New England Local Health District), Gail Matthews (Kirby Institute).